PUB - Publikationen an der Universität Bielefeld

Bischoff, P., Reck, M., Overbeck, T., Christopoulos, P., Rittmeyer, A., Lüders, H., Kollmeier, J., et al. (2024). Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer. Journal of Thoracic Oncology, 19(5), 803-817. https://doi.org/10.1016/j.jtho.2023.12.015

Bischoff, P., Reck, M., Overbeck, T., Christopoulos, P., Rittmeyer, A., Lüders, H., Kollmeier, J., Kulhavy, J., Kemper, M., Reinmuth, N., et al. (2024). Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer. Journal of Thoracic Oncology 19, 803-817.

Bischoff, P., et al., 2024. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer. Journal of Thoracic Oncology, 19(5), p 803-817.

P. Bischoff, et al., “Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer”, Journal of Thoracic Oncology, vol. 19, 2024, pp. 803-817.

Bischoff, P., Reck, M., Overbeck, T., Christopoulos, P., Rittmeyer, A., Lüders, H., Kollmeier, J., Kulhavy, J., Kemper, M., Reinmuth, N., Röper, J., Janning, M., Sommer, L., Aguinarte, L., Koch, M., Wiesweg, M., Wesseler, C., Waller, C.F., Kauffmann-Guerrero, D., Stenzinger, A., Stephan-Falkenau, S., Trautmann, M., Lassmann, S., Tiemann, M., Klauschen, F., Sebastian, M., Griesinger, F., Wolf, J., Loges, S., Frost, N., Hilbrandt, M., Süptitz, J., Grah, C., Velthaus, J.-L., Kopp, H.-G., Schmidt, B., Horter, S., Keymel, S., Aydilek, E., Tritchkova, G., Raspe, M., Papić, D., Florian, S., Horst, D., Wild, P.J., Thomas, M., Grohé, C., Bleckmann, A., Wermke, M., Hummel, H.-D., Stratmann, J., Schütte, W.: Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer. Journal of Thoracic Oncology. 19, 803-817 (2024).

Bischoff, Philip, Reck, Martin, Overbeck, Tobias, Christopoulos, Petros, Rittmeyer, Achim, Lüders, Heike, Kollmeier, Jens, Kulhavy, Jonas, Kemper, Marcel, Reinmuth, Niels, Röper, Julia, Janning, Melanie, Sommer, Linna, Aguinarte, Lukas, Koch, Myriam, Wiesweg, Marcel, Wesseler, Claas, Waller, Cornelius F., Kauffmann-Guerrero, Diego, Stenzinger, Albrecht, Stephan-Falkenau, Susann, Trautmann, Marcel, Lassmann, Silke, Tiemann, Markus, Klauschen, Frederick, Sebastian, Martin, Griesinger, Frank, Wolf, Jürgen, Loges, Sonja, Frost, Nikolaj, Hilbrandt, Moritz, Süptitz, Juliane, Grah, Christian, Velthaus, Janna-Lisa, Kopp, Hans-Georg, Schmidt, Bernd, Horter, Susanne, Keymel, Stefanie, Aydilek, Enver, Tritchkova, Guergana, Raspe, Matthias, Papić, Dražen, Florian, Stefan, Horst, David, Wild, Peter J., Thomas, Michael, Grohé, Christian, Bleckmann, Annalen, Wermke, Martin, Hummel, Horst-Dieter, Stratmann, Jan, and Schütte, Wolfgang. “Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer”. Journal of Thoracic Oncology 19.5 (2024): 803-817.